Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Lilly receives FDA approval for ZYPREXA RELPREVV

Lilly receives FDA approval for ZYPREXA RELPREVV

16th December 2009

Lilly has been granted Food and Drug Administration (FDA) approval for its adult schizophrenia treatment ZYPREXA RELPREVV (olanzapine).

In a statement, the pharmaceutical organisation explained that the therapy, which is a long-acting intramuscular injection, sustains delivery of olanzapine for a period of up to one month.

Dr John Hayes, vice-president of Lilly Research Laboratories, said that non-adherence to treatment is a more significant barrier to care for people who suffer from schizophrenia than was previously appreciated.

As such, he said that long-acting treatments can play a hugely beneficial role in helping people who suffer from the condition to stick to a stable treatment regimen.

“ZYPREXA RELPREVV provides a new mechanism for helping appropriate patients benefit from the well-characterised efficacy of olanzapine,” Dr Hayes concluded.

Earlier this month, Lilly announced that its operations have grown to such an extent that it is now the ninth largest company in terms of global pharmaceutical sales, based on IMS data for the year ended June 2009.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.